Macrolide-Resistant Pneumococcus in Community-Acquired Pneumonia is There Still a Role for Macrolide Therapy?

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 11, 2015, Pages 1216-1217

  Niederman, Michael S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; MACROLIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTIFICIAL VENTILATION; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; EDITORIAL; HUMAN; INTENSIVE CARE UNIT; MACROLIDE RESISTANT PNEUMOCOCCUS; MACROPHAGE; MONOTHERAPY; NONHUMAN; NONINVASIVE VENTILATION; PENICILLIN RESISTANCE; PHAGOCYTOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIORITY JOURNAL; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; ANTIBIOTIC RESISTANCE; FEMALE; MALE; PNEUMONIA, PNEUMOCOCCAL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; MACROLIDES; MALE; PNEUMONIA, PNEUMOCOCCAL;

EID: 84930448670     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201504-0701ED     Document Type: Editorial

References (11)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
2. Low DE. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (Should macrolide monotherapy be used for mild pneumonia?) Infect Dis Clin North Am 2013;27:87-97.
3. Zhanel GG, Wolter KD, Calciu C, Hogan P, Low DE, Weiss K, Karlowsky JA. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data. J Antimicrob Chemother 2014;69:2835-2840.
4. Cilloniz C, Albert RK, Liapikou A, Gabarrus A, Rangel E, Bello S, Marco F, Mensa J, Torres A. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med 2015;191: 1265-1272.
5. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012;68:479-503.
6. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics-part 1: biological mechanisms. Respiration 2011;81:67-74.
7. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, et al.; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-444.
8. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014;42:420-432.
9. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009;33:153-159.
10. Garin N, GennéD, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, et al. b-Lactam monotherapy vs b-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014;174:1894-1901.
11. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, et al.; CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372:1312-1323.